Sol-Gel Technologies Ltd.
SLGLHealthcare|Biotechnology|IL
$61.01
-2.00 (-3.17%)
Tangible Book / Share
$14.71
Cash / Share
$14.65
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04308395 Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | Basal Cell Nevus Syndrome | P3 | Terminated | 108 | Open-label | Patidegib Topical Gel, 2% |
| NCT03761810 A Study of S6G5T3 in the Treatment of Acne Vulgaris | Acne Vulgaris | P3 | Completed | 434 | RCT, Double-blind | S6G5T-3, S6G5T-8 |
| NCT03761784 A Study of S6G5T-3 in the Treatment of Acne Vulgaris | Acne Vulgaris | P3 | Completed | 424 | RCT, Double-blind | S6G5T-3, S6G5T-8 |
| NCT03448939 A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea | Papulopustular Rosacea | P3 | Completed | 361 | RCT, Double-blind | S5G4T-1, S5G4T-2 |
| NCT03564119 A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea | Papulopustular Rosacea | P3 | Completed | 372 | RCT, Double-blind | S5G4T-1, S5G4T-2 |
| NCT03703310 Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) | Basal Cell Nevus Syndrome | P3 | Completed | 174 | RCT, Double-blind | Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle |
| NCT03727074 Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream | Actinic Keratosis (AK) | P3 | Completed | 462 | RCT, Double-blind | 5-FU Cream, Efudex®, Vehicle |
| NCT03564145 A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea | Papulopustular Rosacea | P3 | Terminated | 547 | Open-label | S5G4T-1 |
| NCT06050122 Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome | Gorlin Syndrome | P3 | Completed | 113 | RCT, Double-blind | Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib |
| NCT04155190 A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | Recurrent Basal Cell Carcinoma | P2 | Terminated | 50 | RCT, Double-blind | Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle |
| NCT00940992 A Study of DER 45-EV Gel to Treat Rosacea | Rosacea | P2 | Completed | 92 | RCT, Double-blind | DER 45 EV, Vehicle |
| NCT02661958 Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris | Acne Vulgaris | P2 | Completed | 726 | RCT, Double-blind | S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8 |
| NCT02842021 Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis | Tinea Pedis | P2 | Terminated | 283 | RCT, Double-blind | S2G6T-1, S2G6T-2, S2G6T-3, S2G6T-4 |
| NCT04059523 MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 | Acne Vulgaris | P1 | Completed | 62 | RCT, Open-label | S6G5T-3, Retin-A® 0.1% Cream |
| NCT05675501 Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties | Papulopustular Rosacea | P1 | Completed | 31 | RCT, Double-blind | Encapsulated Benzoyl Peroxide Cream |